Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder

References

• Depression Guideline Panel. Treatment of Major Depression. 2, AHCPR 93-0551, No. 5. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Policy and Research, 1993
   Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28–40
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006; 75: 139–153
   PubMed Web of Science ®Google Scholar
• Rush AJ, Carmody TJ, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000; 9: 45–59
   Google Scholar
• Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34: 73–82
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573–583
   PubMed Web of Science ®Google Scholar
• Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 2006; 59: 493–501
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231–1242
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243–1252
   PubMed Web of Science ®Google Scholar
• Unutzer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 2002; 288: 2836–2845
   PubMed Web of Science ®Google Scholar
• Rush AJ, Crismon ML, Kashner TM, et al. Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry 2003; 64: 357–369
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry 2004; 56: 46–53
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004; 61: 669–680
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–1917
   PubMed Web of Science ®Google Scholar
• Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843–853
   PubMed Web of Science ®Google Scholar
• McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007; 24: 487–494
   PubMed Web of Science ®Google Scholar
• El-Khalili, N, Joyce, M, Atkinson, S, , et al. Adjunctive ER quetiapine fumarate XR in patients with MDD and inadequate antidepressant response. In. Program and Abstracts of the American Psychiatric Association. 161st Annual Meeting, May 3–8, 2008, Washington, DC. Abstract NR3-088
   Google Scholar
• Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008; 23: 269–275
   PubMed Web of Science ®Google Scholar
• Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007; 68: 1071–1077
   PubMed Web of Science ®Google Scholar
• Gharabawi G, Canuso C, Pandina G, et al. A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder. Int J Neuropsychopharmacol 2006; 9(Suppl I)S236
   Google Scholar
• McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65(Suppl 18)47–56
   PubMed Web of Science ®Google Scholar
• Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005; 86: 99–104
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004; 26: 649–666
   PubMed Web of Science ®Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004; 16: 189–194
   PubMedGoogle Scholar
• Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005; 66: 1326–1330
   PubMed Web of Science ®Google Scholar
• Worthington JJ III, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005; 20: 9–11
   PubMed Web of Science ®Google Scholar
• Patkar AA, Peindl K, Mago R, Mannelli P, Masand PS. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006; 8(2)82–87
   PubMedGoogle Scholar
• Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400–1411
   PubMed Web of Science ®Google Scholar
• Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) 2007; 191: 745–758
   PubMed Web of Science ®Google Scholar
• Sheehan, DV, Lecrubier, Y, Sheehan, KH, , et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Suppl 20):22–33, quiz: 34–57
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278–296
   PubMed Web of Science ®Google Scholar
• Wisniewski, SR, Rush, AJ, Balasubramani, GK, Trivedi, MH, Nierenberg, AA, for the STARD Investigators. Self-rated global measure of the frequency, intensity, and burden of side-effects. J Psychiatr Pract 2006; 12(2):71–79.
   PubMedGoogle Scholar
• Rush AJ, Trivedi MH, Carmody TJ, et al. Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology 2005; 30: 405–416
   PubMed Web of Science ®Google Scholar
• Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 1995; 273: 1026–1031
   PubMed Web of Science ®Google Scholar
• Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side-effects in clinical trials. Psychopharmacol Bull 1986; 22: 343–381
   PubMed Web of Science ®Google Scholar
• Levine J, Schooler NR. General versus specific inquiry with SAFTEE. J Clin Psychopharmacol 1992; 12: 448
   PubMed Web of Science ®Google Scholar
• Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–676
   PubMed Web of Science ®Google Scholar
• Guy, W. ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Health,
   Google Scholar
• Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988; 39: 1172–1177
   PubMedGoogle Scholar
• Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003; 49: 156–163
   PubMed Web of Science ®Google Scholar
• Rossby SP, Manier DH, Liang S, Nalepa I, Sulser F. Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors. Int J Neuropsychopharmacol 1999; 2: 1–8
   PubMed Web of Science ®Google Scholar
• Xu H, Steven Richardson J, Li XM. Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 2003; 28: 53–62
   PubMed Web of Science ®Google Scholar
• Khawaja X, Xu J, Liang JJ, Barrett JE. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J Neurosci Res 2004; 75: 451–460
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381–389
   PubMed Web of Science ®Google Scholar
• Aihara K, Shimada J, Miwa T, et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res 2004; 1003: 9–17
   PubMed Web of Science ®Google Scholar
• Stark AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 2007; 190: 373–382
   PubMed Web of Science ®Google Scholar